A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer - Trial NCT06211023
Access comprehensive clinical trial information for NCT06211023 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and is currently Not yet recruiting. The study focuses on Ovarian Cancer. Target enrollment is 520 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Timeline & Enrollment
Phase 2/3
Feb 15, 2024
Jun 15, 2026
Primary Outcome
Objective Response Rate Assessed by Investigator According to RECIST v1.1
Summary
This is an open-label, randomized, controlled, two-part study to evaluate the safety and
 efficacy of SHR-A1921 with or without carboplatin verus investigator's choice of
 platinum-based doublet chemotherapy in subjects with recurrent epithelial ovarian cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06211023
Non-Device Trial